| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 16, 2021 | ORGO Organogenesis Holdings Inc. | Gillheeney Gary S.73 | President And CEO | Sell | 291,862 | $13.32 | $3,886,852.41 | -18.9% | - | - | |
| Feb 12, 2021 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Buy | 1,000 | $20.03 | $20,030.00 | +8.2% | - | - | |
| Feb 12, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 48,847 | $18.93 | $924,750.44 | -0.2% | +3.6% | +43.8% | |
| Feb 11, 2021 | ORGO Organogenesis Holdings Inc. | Ades Alan A. | Director, 10% Owner | Sell | 200,000 | $3.25 | $650,000.00 | -0.3% | - | - | |
| Feb 11, 2021 | ZTS Zoetis Inc. | Kelly Robert Edward | Executive Vice President | Sell | 2,054 | $161.15 | $331,002.10 | -19.1% | +2.3% | +21.6% | |
| Feb 11, 2021 | ORGO Organogenesis Holdings Inc. | Nussdorf Glenn H75 | Director, 10% Owner | Sell | 200,000 | $3.25 | $650,000.00 | -0.3% | - | - | |
| Feb 11, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 1,400 | $11.88 | $16,632.00 | +17.5% | - | - | |
| Feb 11, 2021 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 7,898 | $25.21 | $199,132.34 | -4.4% | - | - | |
| Feb 10, 2021 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 1,700 | $119.96 | $203,925.55 | -2.5% | - | - | |
| Feb 10, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $11.64 | $23,280.00 | +33.3% | - | - | |
| Feb 10, 2021 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Sell | 35,000 | $6.75 | $236,250.00 | -2.0% | -50.2% | -60.8% | |
| Feb 10, 2021 | KNSA Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | Chairman &CEO | Sell | 56,159 | $23.05 | $1,294,534.15 | -16.9% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 29,496 | $12.69 | $374,436.97 | -11.6% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 65,312 | $12.69 | $829,103.18 | -52.7% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 29,657 | $12.69 | $376,480.79 | -17.2% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, International Markets | Sell | 21,635 | $12.72 | $275,216.67 | -13.5% | - | - | |
| Feb 9, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $12.06 | $24,120.00 | +50.0% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 17,979 | $12.72 | $228,709.06 | -16.7% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 20,694 | $12.69 | $262,699.98 | -10.7% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 68,422 | $12.72 | $870,389.42 | -47.1% | - | - | |
| Feb 9, 2021 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 20,000 | $22.94 | $458,812.00 | -40.0% | - | - | |
| Feb 9, 2021 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 40,206 | $116.19 | $4,671,507.39 | -14.7% | - | - | |
| Feb 9, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 40,886 | $18.92 | $773,546.00 | -0.2% | +1.2% | +37.7% | |
| Feb 8, 2021 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Sell | 40,792 | $6.50 | $265,148.00 | -4.5% | -47.6% | -61.0% | |
| Feb 8, 2021 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 2,363 | $116.78 | $275,943.91 | -6.2% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.